Patent · US Active

Quinazoline compound for EGFR inhibition

US11040984B2 · kind B2 · utility

0Cited by

4References

24Claims

0Family size

Assignee

Medshine Discovery Inc. · CN

Inventors

Xile LIU · Shanghai, CN
Charles Z. Ding · San Mateo, US
Shuhui CHEN · Shanghai, CN
Lingyun WU · Shanghai, CN
Lihong Hu · Shanghai, CN
Haiwen Wan · Shanghai, CN

Key dates

Filing date	Dec 29, 2017
Grant date	Jun 22, 2021
Priority date	—
Expiry date	Dec 29, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.